Nothing Special   »   [go: up one dir, main page]

FR2828102B1 - Utilisation des lipoaminoacides dans une composition pharmaceutique comme promoteur et systeme disperse a usage pharmaceutique contenant de tels composes - Google Patents

Utilisation des lipoaminoacides dans une composition pharmaceutique comme promoteur et systeme disperse a usage pharmaceutique contenant de tels composes

Info

Publication number
FR2828102B1
FR2828102B1 FR0107051A FR0107051A FR2828102B1 FR 2828102 B1 FR2828102 B1 FR 2828102B1 FR 0107051 A FR0107051 A FR 0107051A FR 0107051 A FR0107051 A FR 0107051A FR 2828102 B1 FR2828102 B1 FR 2828102B1
Authority
FR
France
Prior art keywords
pharmaceutical
lipoaminoacids
promoter
compounds
disperse system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0107051A
Other languages
English (en)
Other versions
FR2828102A1 (fr
Inventor
Nicolas Calvet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IFC SA
Original Assignee
IFC SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0104187A external-priority patent/FR2828101A1/fr
Application filed by IFC SA filed Critical IFC SA
Priority to FR0107051A priority Critical patent/FR2828102B1/fr
Priority to US10/473,312 priority patent/US20040147578A1/en
Priority to EP02724387A priority patent/EP1372730A1/fr
Priority to CA002441824A priority patent/CA2441824A1/fr
Priority to PCT/FR2002/001101 priority patent/WO2002076506A1/fr
Publication of FR2828102A1 publication Critical patent/FR2828102A1/fr
Application granted granted Critical
Publication of FR2828102B1 publication Critical patent/FR2828102B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR0107051A 2001-03-28 2001-05-30 Utilisation des lipoaminoacides dans une composition pharmaceutique comme promoteur et systeme disperse a usage pharmaceutique contenant de tels composes Expired - Fee Related FR2828102B1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
FR0107051A FR2828102B1 (fr) 2001-03-28 2001-05-30 Utilisation des lipoaminoacides dans une composition pharmaceutique comme promoteur et systeme disperse a usage pharmaceutique contenant de tels composes
US10/473,312 US20040147578A1 (en) 2001-03-28 2002-03-28 Use of lipoaminoacids as absorption promoters in a pharmaceutical composition
EP02724387A EP1372730A1 (fr) 2001-03-28 2002-03-28 Utilisation de lipoaminoacides comme promoteurs d'absorption dans une composition pharmaceutique
CA002441824A CA2441824A1 (fr) 2001-03-28 2002-03-28 Utilisation de lipoaminoacides comme promoteurs d'absorption dans une composition pharmaceutique
PCT/FR2002/001101 WO2002076506A1 (fr) 2001-03-28 2002-03-28 Utilisation de lipoaminoacides comme promoteurs d'absorption dans une composition pharmaceutique

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0104187A FR2828101A1 (fr) 2001-03-28 2001-03-28 Utilisation des lipoaminoacides dans une composition pharmaceutique comme promoteurs d'absorption et systeme disperse a usage pharmaceutique contenant de tels composes
FR0107051A FR2828102B1 (fr) 2001-03-28 2001-05-30 Utilisation des lipoaminoacides dans une composition pharmaceutique comme promoteur et systeme disperse a usage pharmaceutique contenant de tels composes

Publications (2)

Publication Number Publication Date
FR2828102A1 FR2828102A1 (fr) 2003-02-07
FR2828102B1 true FR2828102B1 (fr) 2004-07-09

Family

ID=26212940

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0107051A Expired - Fee Related FR2828102B1 (fr) 2001-03-28 2001-05-30 Utilisation des lipoaminoacides dans une composition pharmaceutique comme promoteur et systeme disperse a usage pharmaceutique contenant de tels composes

Country Status (5)

Country Link
US (1) US20040147578A1 (fr)
EP (1) EP1372730A1 (fr)
CA (1) CA2441824A1 (fr)
FR (1) FR2828102B1 (fr)
WO (1) WO2002076506A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2834215B1 (fr) * 2001-12-27 2004-07-16 Physica Composes amphiphiles a usage pharmaceutique ou cosmetique
CN101160323A (zh) * 2005-04-15 2008-04-09 拉帕波特家族医学科学研究所 用于治疗mcp-1/ccr2相关疾病的分子及其使用方法
ITRM20080551A1 (it) * 2008-10-15 2010-04-16 Univ Catania Derivati anfifilici del poliossietilenglicole (peg), procedimento di preparazione e loro usi nella preparazione di sistemi farmaceutici.
FR2959936B1 (fr) 2010-05-14 2012-08-03 Physica Pharma Composition nasales a visee systemique a base de cocoyl proline ou d 'au moins un de ses constituants
FR2971943B1 (fr) * 2011-02-24 2013-08-02 Physica Pharma Compositions pharmaceutiques a action locale administrables par application cutanee
FR2971941B1 (fr) 2011-02-24 2013-08-02 Physica Pharma Compositions pharmaceutiques administrables par voie cutanee et destinees au traitement local de la dermatite atopique canine
EP2696847A1 (fr) * 2011-04-14 2014-02-19 Novo Nordisk A/S Acides aminés acylés par un acide gras pour l'administration de peptides par voie orale
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
MX365818B (es) 2011-11-23 2019-05-30 Therapeuticsmd Inc Formulaciones y terapias de reemplazo hormonal de combinacion naturales.
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
JP6285447B2 (ja) * 2012-10-17 2018-02-28 ノヴォ ノルディスク アー／エス 経口ペプチド送達用の脂肪酸アシル化ｄ−アミノ酸
EP2908844A1 (fr) * 2012-10-17 2015-08-26 Novo Nordisk A/S Acides aminés acylés par un acide gras pour l'administration de peptides par voie orale
WO2014060512A1 (fr) * 2012-10-17 2014-04-24 Novo Nordisk Health Care Ag Acides aminés acylés par un acide gras pour l'administration d'hormone de croissance
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
WO2015162195A1 (fr) * 2014-04-23 2015-10-29 Novo Nordisk A/S Acides aminés acylés par un acide gras pour l'administration de peptides par voie orale
CA2947767A1 (fr) 2014-05-22 2015-11-26 Therapeuticsmd, Inc. Formulations d'hormones substitutives combinees naturelles et traitement hormonal substitutif
JP2017523138A (ja) * 2014-07-29 2017-08-17 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 経皮クリーム
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4442090A (en) * 1980-11-09 1984-04-10 Kyoto Yakuhin Kogyo Kabushiki Kaisha Absorption-promoting compounds, compositions thereof with pharmaceuticals and/or bases for rectal administration and method of use
JPS5788126A (en) * 1980-11-19 1982-06-01 Kyoto Yakuhin Kogyo Kk Agent for promoting peroral and transvaginal absorption and preparation containing the same
DE3382112D1 (de) * 1982-04-30 1991-02-21 Ajinomoto Kk Pharmazeutische zusammensetzung.
JPS5980326A (ja) * 1982-10-29 1984-05-09 Kobayashi Kooc:Kk Ｗ／ｏ／ｗ型エマルジヨンの製造方法
US4837026A (en) * 1985-10-03 1989-06-06 Rajakhyaksha Vithal J Transdermal and systemic preparation and method
JP2911496B2 (ja) * 1989-09-11 1999-06-23 帝國製薬株式会社 生理活性ポリペプチド含有高吸収性経膣剤
JP3202777B2 (ja) * 1992-01-24 2001-08-27 リンテック株式会社 経皮吸収促進剤及びテープ製剤
JPH05310552A (ja) * 1992-05-13 1993-11-22 Kanebo Ltd 皮膚外用剤
ATE333867T1 (de) * 1994-03-18 2006-08-15 Shire Lab Inc Emulgierte arzneistoffabgabesysteme

Also Published As

Publication number Publication date
WO2002076506A1 (fr) 2002-10-03
CA2441824A1 (fr) 2002-10-03
EP1372730A1 (fr) 2004-01-02
US20040147578A1 (en) 2004-07-29
FR2828102A1 (fr) 2003-02-07

Similar Documents

Publication Publication Date Title
FR2828102B1 (fr) Utilisation des lipoaminoacides dans une composition pharmaceutique comme promoteur et systeme disperse a usage pharmaceutique contenant de tels composes
TNSN00191A1 (fr) Composes nouveaux, compositions les contenant et leur utilisation dans le traitement d'une ischemie
IL127955A0 (en) Pharmaceutical composition containing acid addition salt of basic drug
FR10C0024I2 (fr) Formulations liquides contenant une gonadotropine
HUP0400974A3 (en) Peptide-based compounds and pharmaceutical compositions containing them
ID25633A (id) Alat untuk penghantar cairan yang mengandung obat-obatan
IL148489A0 (en) Quinazoline compounds and pharmaceutical compositions containing them
FR2834890B1 (fr) Composition pharmaceutique orodispersible d'agomelatine
HUP0203939A3 (en) Pharmaceutical compounds and compositions containing them and their use
HUP0600593A2 (en) Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents and pharmaceutical compositions thereof
TNSN98113A1 (fr) Procede de preparation de composes utiles pour le traitement de la resistance a l'insuline.
HUP0100186A3 (en) Compounds as lactam metalloprotease inhibitors and pharmaceutical compositions containing them
MA27026A1 (fr) Composition pharmaceutique liquide
DK1156806T3 (da) Farmaceutisk sammensætning indeholdende protonpumpeinhibitor
HK1149719A1 (en) Ciclesonide contained pharmaceutical composition for application to mucosa
HUP0200638A2 (en) Compounds derived from benzoic acid esters, composition containing said compounds and use thereof
HUP0002951A3 (en) Bis-aminomethylcarbonyl compounds as protease inhibitors and pharmaceutical compositions containing them
HUP0201911A3 (en) Aminobenzophenones as inhibitors of il-1betha and tnf-alpha and pharmaceutical compositions containing them
PL367128A1 (en) Chemical compounds and pharmaceutical compositions as cathepsin s inhibitors
FR2857263B1 (fr) Nouvelle composition pharmaceutique solide comprenant de l'amisulpride
FR2834896B1 (fr) Composition pharmaceutique orodispersible d'ivabradine
FR2850866B1 (fr) Melange de latex inverse auto-inversible et d'une poudre a usage cosmetique ou pharmaceutique; utilisation comme agent de texture
ID22416A (id) Komposisi-komposisi farmasi yang mengandung ibuprofen dan domperidon untuk pengobatan migrain
AU2002302685A1 (en) Use of compounds modulating rxr-ppar heterodimer activity as medicine for treating hepatitis c
HU9800395D0 (en) Sulfonamide-substituted anellated compounds of seven ring, their use as medicines and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 15

PLFP Fee payment

Year of fee payment: 16

PLFP Fee payment

Year of fee payment: 17

PLFP Fee payment

Year of fee payment: 18

PLFP Fee payment

Year of fee payment: 19

ST Notification of lapse

Effective date: 20210105